Amphithéâtre Guillaume Budé, Site Marcelin Berthelot
Open to all
-

Abstract

The discovery of numerous and frequent mutations in epigenome modifiers have highlighted the importance of epigenetic mechanisms in cancer. In addition, epimutations such as aberrant DNA met hylation have been reported to constitute the most frequent changes in many cancers. To gain insights into the underlying mechanisms and potential therapeutic targets, we have analysed a range of cancer methylomes in the context of additional perturbations such as specifie mutations, viral infection and reprogramming.

References

Lechner M., Fen ton T., West J., Wilson G., Feber A., Henderson S., Thirl well C., Dibra H.K., Jay A., Butcher L., Chakravarthy A.R., Gratrix F., Patel N., Vaz F., O'Flynn P., Kalavrezos N., Teschendorff A.E., Boshoff C., Beek S., "Identification and functional validation of HPV-mediated hypermet h ylation in head and neck squamous cell carcinoma", Genome Med. 2013 Feb 18;5(2):15.

Stricker S.H., Feber A., Engst rom P., Caren H., Kurian K.M., Takashima Y., Watts C., Way M., Dirks P., Bertone P., Smith A., Beck S., Pollard S.M., "Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner", Genes & Development. In press.

Guilhamon P., Eskandarpou M., Hala D., Wilson G.A., Feber A., Teschendorff A.E., Tirabosco R., Amary F., Baum hoer D., Jundt G., Ross M.T., Flanagan A.M., Beek S., "Meta-anal ysis of IDH mutant med iated hypermethylation identifies tissue-specifie effectors within a shared pathway in multiple cancers". Submitted.

Speaker(s)

Stephan Beck

UCL Cancer Institute, London, UK